RedPath Integrated Pathology
Healthcare Services · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2515 Liberty Ave, Pittsburgh, Pennsylvan...Phone Number
(412) 224-6100Website
www.npcnregistry.comRevenue
$16.5 MillionIndustry
About RedPath Integrated Pathology
The National Pancreatic Cyst Registry is a prospective study focusing on Integrated Molecular Pathology (IMP) to predict the malignancy of pancreatic cysts. It collaborates with leading academic medical centers and community-based practices to assess the performance characteristics and clinical utility of IMP alongside traditional tests. The study specifically evaluates the efficacy of PathFinderTG (PancraGEN) in risk-stratifying patients based on malignancy potential. Sponsored in part by RedPath Integrated Pathology, Inc. (Interpace Diagnostics), the registry aims to advance understanding and management of pancreatic cysts.Explore more
RedPath Integrated Pathology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to RedPath Integrated Pathology
Compare insights from companies similar to RedPath Integrated Pathology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
RedPath Integrated Pathology Tech Stack
A closer look at the technologies used by RedPath Integrated Pathology
See more technologies
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RedPath Integrated Pathology
Sign Up For FreeTo access detailed company insights
The National Pancreatic Cyst Registry is a prospective study focusing on Integrated Molecular Pathology (IMP) to predict the malignancy of pancreatic cysts. It collaborates with leading academic medical centers and community-based practices to assess the performance characteristics and clinical utility of IMP alongside traditional tests. The study... Read More
